Stopping anti-rejection medicine after liver transplant in children
Part of Digestive system, Immune system & allergy clinical trials.
This study looks at whether it is safe to stop or reduce anti-rejection medicines in children who have had a liver transplant for at least 4 years and are doing well. The goal is to see if they can live without these medicines and their side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child was under 6 years old at the time of liver transplant
- At least 4 years have passed since the transplant
- Liver function is currently normal and stable
- Taking only one anti-rejection medicine (tacrolimus or cyclosporine)
- A liver biopsy in the last 2 years showed no rejection or significant scarring
- No hepatitis infection in the last year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach to managing anti-rejection medicines after a heart transplant. It uses special blood tests to see if your immune system is calm, so doctors can safely reduce the medicines and lower side effects.
This trial uses a special ultrasound (Fibroscan) to check your liver health and see if you can safely reduce your anti-rejection medications. It is for people who are at least 2 years past a liver transplant and whose liver is working well.
This study tests whether long-term liver transplant recipients (5+ years after transplant) can safely stop or reduce their immunosuppressant medications by checking for donor cells (chimerism) in the liver. If you have stable liver function and agree to a liver biopsy, you may be able to join.
This study tests whether some older adults who have had a kidney transplant for more than a year can safely stop taking one of their anti-rejection medicines (mycophenolate mofetil, or MMF) instead of staying on it long-term. If you qualify, you may be able to reduce your daily pill burden while keeping your new kidney safe.
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
This trial tests whether switching from a standard anti-rejection medicine to a different one (everolimus) about a year after a liver transplant can help protect your new liver with fewer side effects. If you qualify, you will be monitored closely for a few years to see how well the new medicine works for you.
Hear when a new Immune Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.